DNDi and Cipla to develop antiretroviral drug combination
New formulation to provide appropriate HIV medicines for infants and young children
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Taro’s Special Committee rejects proposal from Sun Pharma
Offer deemed "inadequate, not in the best interests of Taro’s minority shareholders"
Domestic pharma companies likely to see steady growth in Q1 FY13: Analysts
Tax rates hikes and forex losses could however cloud the picture for certain companies
Zydus Urosciences launches Udenafil
The inhibitor has been launched for the first time in India to cure erectile dysfunction
Canada-India Business Council signs MoU with Gujarat govt
To focus on sectors like pharmaceuticals, telecom, energy and finance
Novartis Q2 result enhances future growth prospects
Achieves eight significant regulatory milestones in the same quarter
A Lakshman Rekha in pharma FDI
Policy makers in India need to adapt fast to new realities and move forward like other global regulators
Proparco invests in Strides’ African arm
Funding to build additional manufacturing infrastructure in key markets in Africa
Pharmexcil to host Japanese delegation
To conduct meetings at New Delhi and Mumbai on July 26 and 27
US FDA: More than 150 ARVs available through PEPFAR for worldwide HIV/AIDS relief
Four Indian companies (Cipla, Hetero Labs, Micro Labs, Edict Pharmaceuticals) are the most recent to receive tentative approvals…